The prevalence and pharmacological cost of Parkinson's disease in Spain;Prevalencia y coste farmacológico de la enfermedad de Parkinson en España

Revista de Neurologia

Volumn 43, Issue 11, 2006, Pages 641-645

  Abasolo Osinaga, Eider ^a   Abecia Inchaurregui, L C ^a   Fernandez Diaz E ^a   Barcenilla Laguna, A ^a   Banares Onraita T ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anti parkinson drugs; Defined daily dose; Levodopa; Parkinson's disease; Pharmacoepidemiology; Prevalence

Indexed keywords

BIPERIDEN; BROMOCRIPTINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT;

ARTICLE; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; PARKINSON DISEASE; PREVALENCE; SPAIN; TIME SERIES ANALYSIS; CLASSIFICATION; COMPARATIVE STUDY; DRUG COST; ECONOMICS; PHARMACY; RETROSPECTIVE STUDY; STATISTICS;

ANTIPARKINSON AGENTS; DRUG COSTS; HUMANS; PARKINSON DISEASE; PHARMACIES; PREVALENCE; RETROSPECTIVE STUDIES; SPAIN;

EID: 35348841055     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4311.2005683     Document Type: Article

References (28)

1. Thomson F, Muir A, Stirton J, Macphee G, Hudson S. Parkinson's disease. The Pharmaceutical Journal 2001; 267: 600-612.
2. Montané E, Vallano A, Castel JM. Evolución del consumo de fármacos antiparkinsonianos en España. Rev Neurol 2002; 34: 612-7.
3. Benito-León J, Porta-Etessam J, Bermejo F. Epidemiología de la enfermedad de Parkinson. Neurología 1998; 13 (Suppl 1): 2-7.
4. Martínez-Suárez MM, Blázquez-Menes B. Estimación de la prevalencia de Parkinson en Asturias (España). Estudio farmacoepidemiológico del consumo de antiparkinsonianos. Rev Neurol 2000; 31: 1001-6.
5. Pérgola F. Reseña epidemiológica de la enfermedad de Parkinson. Revista de la Asociación Médica Argentina [on line]. URL: http://www.ama-med.org.ar/publicaciones_revistas3. Fecha última consulta: 23.02.2005.
6. Nordic Council on Medicines. WHO Collaborating Centre for Drugs Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index. Including defined daily doses (DDDs) for plain substances. Oslo: WHO Collaborating Centre for Drugs Statistics Methodology; 2001.
7. Schubert I. Drug utilization in Europe -report of the EURO-DRUG Workshop and Joint Symposium with the EACPT Berlin 16.9-18.9 1997. European Drug Utilization Research Group. European Association for Clinical Pharmacology and Therapeutics. Int J Clin Pharmacol Ther 1998; 36: 176-9.
8. Laporte JR, Tognoni G. Estudios de utilización de medicamentos y de farmacovigilancia. In Laporte JR, Tognoni G, eds. Principios de epidemiología del medicamento. Barcelona: Masson-Salvat Medicina; 1993. p. 1-24.
9. Sevillano MD, Cuadrado JI, de Pedro J. Enfermedad de Parkinson en España: evidencias de infradiagnóstico y puntos de partida para su reducción. Rev Neurol 1999; 29: 881-3.
10. Sevillano MD, De Pedro-Cuesta J, Duarte J, Clavería LE. Field validation of a method for population screening of parkinsonism. Mov Disord 2002; 17: 258-64.
11. Chen RC, Chang SF, Su CL, Chen THH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD. A door-to-door survey in Ilan County, Taiwan. Neurology 2001; 57: 1679-86.
12. De Pedro-Cuesta J, Pettersen IJ, Vassilopoulos D, Micheli F, García-Inesta A. Epidemiological assessment of levodopa use by populations. Acta Neurol Scand 1991; 83: 328-35.
13. Costa C, Castiñeira MC. Enfermedad de Parkinson. Guías Clínicas Fisterra [on line]. URL: http://www.fisterra.com/guias2/ parkinson.htm. Fecha última consulta: 24.05.2005.
14. De Pedro-Cuesta J, Cuadrado JI. Evaluación epidemiológica de consumo de levodopa. Rev Neurol 2000; 31: 1028-30.
15. Limón-Mendizábal C, García A, Ortega A. Utilización de levodopa en España en el período 1982-1984. Inf Ter Segur Soc 1985; 9: 202-10.
16. Artázcoz MT, Viñes JJ. Estimación de la prevalencia de la enfermedad de Parkinson en Navarra. Estudio farmacoepidemiológico del consumo de antiparkinsonianos. Rev Esp Salud Pública 1995; 69: 479-85.
17. Criado-Álvarez JJ, Romo-Barrientos C, Martínez- Hernández J, González-Solana I. Consumo de antiparkinsonianos en Castilla-La Mancha. Estimación de la prevalencia de la enfermedad de Parkinson. Rev Neurol 1998; 27: 405-8.
18. Burguera JA, Catalá J, Taberner P, Muñoz R. Mortalidad por enfermedad de Parkinson en España (1980-1985). Distribución por edades, sexo y áreas geográficas. Neurología 1992; 7: 89-93.
19. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality of levodopa and levodopa combined with selegilina in patients with early, mild Parkinson's disease. BMJ 1995; 311:1602-7.
20. Ben-Sholomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191-6.
21. Heinonen EH, Myllyva V, Safety of selegiline (Deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998; 19: 11-22.
22. Breteler MMB. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be. BMJ 1998; 316: 1182-3.
23. Thorogood M, Amstrong B, Nichols T, Hollowell J. Mortality in people taking selegiline: observational study. BMJ 1998; 317: 252-4.
24. Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998; 51: 825-30.
25. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol 1998; 43: 318-25.
26. Donan PT, Steinke DT, Stubbings C, Davey PG, McDonald TM. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000; 55: 1785-9.
27. Adler C, Sethi K, Hauser R, Davis T, Hammersted J, Bertoni J, et al. Ropirinole for the treatment of early Parkinson's disease. Neurology 1997; 9: 393-9.
28. Shannon K, Bennett J, Friedman J, for the Parkinson Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49: 724-8.